GeneDx (WGS) Insider Joshua Ruch Buys 4,248 Shares

Joshua Ruch increased his stake in GeneDx Holdings Corp. (NasdaqGS: WGS) on June 18, 2026. Ruch acquired 4,248 shares of the genomics firm on that date. This purchase happened on the same day that Ruch also disposed of 3,576 shares, making for a busy day of activity for the insider. These transactions were disclosed in filings with the Securities and Exchange Commission.

Recent Insider Activity at GeneDx Holdings

The trade by Joshua Ruch was part of a larger wave of activity among the company's leadership during the same week. On June 18, 2026, Eli Casdin also bought 4,248 shares of the stock. Meanwhile, Jason Ryan sold 3,576 shares on that same day. Earlier in the week, on June 16, 2026, Chief Financial Officer Kevin Feeley sold 7,197 shares. None of these transactions were conducted under a Rule 10b5-1 trading plan, which is a tool insiders often use to schedule trades in advance to avoid concerns about having private information.

Stock Performance and Market Position

Shares of GeneDx Holdings were trading at $58.08 on Wednesday. The stock has seen quite a bit of movement lately, as it currently sits between its 52-week low of $32.21 and a 52-week high of $170.87. The current price is trailing its longer-term trends, as the 200-day moving average is $81.82 and the 50-day moving average is $77.96. With a market value of about $2.92 billion, the company is navigating a period where it is not yet profitable, evidenced by its negative earnings per share of -$3.63.

Recent Earnings and Financial Health

In its most recent financial reports, GeneDx Holdings showed revenue of $454.43 million. This represents a growth rate of 11.4% compared to previous periods. While the company is growing its top line, it still faces profitability hurdles, reporting a net margin of -23.4% and a return on equity of -40.8%. The company maintains a healthy liquidity position with a current ratio of 3.30, suggesting it has enough cash and short-term assets to cover its immediate bills. The next earnings report is expected on October 27, 2026.

Analysts Set New Price Targets

Several research firms have recently shared their outlook on GeneDx Holdings. On October 1, 2026, Guggenheim kept a Buy rating on the stock and boosted its price target to $83.00 from $74.00. Earlier, on August 4, 2026, Canaccord Genuity also maintained a Buy rating while raising its target to $90.00. BTIG echoed that $90.00 target on the same day. Piper Sandler has also been active, maintaining an Overweight rating with a $63.00 target as of June 23, 2026. Across nine different analyst opinions, the average price target for the stock is $90.44.

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is a healthcare company based in Stamford, Connecticut, that specializes in genomics. They provide genetic testing services, mostly focusing on rare diseases and pediatric diagnostics. They use advanced whole exome and genome sequencing to help doctors understand complex medical conditions. The company also uses an artificial intelligence platform to help analyze and report on clinical data for cancer testing and hereditary risks.

What's Ahead for GeneDx Holdings Corp.

Investors will likely watch the company's next earnings update in late October to see if the revenue growth continues to outpace its spending. While the recent insider buying from Ruch and Casdin shows some internal interest in the stock, it is important to remember that these SEC filings show past moves and don't always reflect what an insider is doing today. The stock's ability to move back toward its 50-day moving average may be a key indicator for those following its technical performance.